| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 0 | 0 | 0 | 4.258 | 16.296 | 15.651 | 22.425 |
| Total Income - EUR | - | - | - | 0 | 0 | 0 | 4.258 | 22.120 | 28.321 | 28.727 |
| Total Expenses - EUR | - | - | - | 0 | 56 | 3.970 | 20.264 | 35.381 | 19.376 | 25.713 |
| Gross Profit/Loss - EUR | - | - | - | 0 | -56 | -3.970 | -16.005 | -13.260 | 8.945 | 3.014 |
| Net Profit/Loss - EUR | - | - | - | 0 | -56 | -3.970 | -16.048 | -13.423 | 8.662 | 2.789 |
| Employees | - | - | - | 0 | 0 | 4 | 3 | 4 | 1 | 1 |
Check the financial reports for the company - Trebordent Lab S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 58 | 0 | 36.171 | 29.034 | 22.770 | 16.366 | 9.974 |
| Current Assets | - | - | - | 43 | 0 | 39.069 | 1.533 | 1.700 | 4.455 | 7.484 |
| Inventories | - | - | - | 0 | 0 | 98 | 1.205 | 0 | 0 | 136 |
| Receivables | - | - | - | 0 | 0 | 0 | 0 | 0 | 283 | 2.073 |
| Cash | - | - | - | 43 | 0 | 38.971 | 328 | 1.700 | 4.172 | 5.275 |
| Shareholders Funds | - | - | - | 43 | -14 | -3.982 | -19.942 | -33.427 | -24.663 | -27.862 |
| Social Capital | - | - | - | 43 | 42 | 43 | 42 | 43 | 42 | 42 |
| Debts | - | - | - | 58 | 14 | 40.253 | 12.404 | 25.499 | 25.854 | 25.801 |
| Income in Advance | - | - | - | 0 | 0 | 38.969 | 38.105 | 32.398 | 19.629 | 19.520 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "3250 - 3250" | |||||||||
| CAEN Financial Year |
3250
|
|||||||||
Comments - Trebordent Lab S.r.l.